The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Abstract
OBJECTIVE: To examine the effects of donepezil compared with placebo on the preservation of function in patients with AD over a 1-year period. METHODS: This was a prospective, 54-week, double-blind, placebo-controlled, survival to endpoint study. Patients were required to have at entry: a diagnosis of probable AD (National Institute of Neurological and Communicative Disorders and Stroke criteria); Mini-Mental State Examination score of 12 to 20; Clinical Dementia Rating of 1 or 2; modified Hachinski ischemia score < or =4; and capability of performing 8 of 10 instrumental activities of daily living and 5 of 6 basic activities of daily living. Patients (n = 431) were randomized to placebo or donepezil (5 mg/day for 28 days, 10 mg/day thereafter). Outcome measures were the AD Functional Assessment and Change Scale, the Mini-Mental State Examination, and Clinical Dementia Rating scale. At each visit, investigators determined whether predefined criteria for clinically evident decline in functional status had been met. Patients who met the endpoint criteria were discontinued per protocol. RESULTS: Donepezil extended the median time to clinically evident functional decline by 5 months versus placebo. The probability of patients treated with donepezil remaining in the study with no clinically evident functional loss was 51% at 48 weeks, compared with 35% for placebo. The Kaplan-Meier survival curves for the two treatment groups were different (p = 0.002, log-rank test). CONCLUSIONS: Patients with AD continue to show detectable disease progression over time, but treatment with donepezil for 1 year was associated with a 38% reduction in the risk of functional decline compared with placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citationThe American Psychiatric Association (APA)
Strentz, T. (2017) · Psychological Aspects of Crisis Negotiation · doi:10.1201/9781315150581-3 · Cited by 1,850
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
Self-citationAn Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
A 5-month, randomized, placebo-controlled trial of galantamine in AD
Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., Ding, C., & the Galantamine USA- Study Group (2000) · Neurology · doi:10.1212/wnl.54.12.2269 · Cited by 921
Self-citationRaskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Cited by
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Donepezil for dementia due to Alzheimer’s disease.
Birks, J. S., & Harvey, R. J. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub3 · Cited by 1,200
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 727
Rajmohan, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160612 · Cited by 688
Guiding Principles for the Care of Older Adults with Multimorbidity: An Approach for Clinicians
American Geriatrics Society Expert Panel on the Care of Older Adults with Multimorbidity (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.04188.x · Cited by 660
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
Waldemar, G., Dubois, B., Emre, M., Georges, J., McKeith, I. G., Rossor, M., Scheltens, P., Tariska, P., & Winblad, B. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01605.x · Cited by 617
Boustani, M., Peterson, B., Hanson, L., Harris, R., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-11-200306030-00015 · Cited by 576
The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease
Schliebs, R., & Arendt, T. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0579-2 · Cited by 530
Kaduszkiewicz, H., Zimmermann, T., Beck-Bornholdt, H.-P., & van den Bussche, H. (2005) · BMJ · doi:10.1136/bmj.331.7512.321 · Cited by 522
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190 · Cited by 515
Revisiting the cholinergic hypothesis in the development of Alzheimer's disease
Craig, L. A., Hong, N. S., & McDonald, R. J. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2011.03.001 · Cited by 486
Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., & Hung, D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 460
Self-citationRandomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
Self-citationLin, J. S., O’Connor, E., Rossom, R. C., Perdue, L. A., & Eckstrom, E. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-9-201311050-00730 · Cited by 410
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Self-citationBlack, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386
Self-citationCholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Tariot, P. N., Cummings, J. L., Katz, I. R., Mintzer, J., Perdomo, C. A., Schwam, E. M., & Whalen, E. (2001) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2001.t01-1-49266.x · Cited by 370
Self-citationWilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
Qaseem, A., Snow, V., Cross, J. T., Forciea, M. A., Hopkins, R., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00008 · Cited by 354
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 345
Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease
Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V., & Ieni, J. R. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51306.x · Cited by 313
Self-citationCurrent and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Patnode, C. D., Perdue, L. A., Rossom, R. C., Rushkin, M. C., Redmond, N., Thomas, R. G., & Lin, J. S. (2020) · JAMA · doi:10.1001/jama.2019.22258 · Cited by 309
Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial
Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., & Richardson, S. (2004) · Neurology · doi:10.1212/01.wnl.0000134664.80320.92 · Cited by 300
Donepezil for dementia due to Alzheimer's disease
Birks, J., & Harvey, R. J. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001190.pub2 · Cited by 285
Current Treatment for Alzheimer Disease and Future Prospects
Tariot, P. N., & Federoff, H. J. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307004-00005 · Cited by 265
Efficacy of Donepezil in Early-Stage Alzheimer Disease: A Randomized Placebo-Controlled Trial
Seltzer, B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.12.1852 · Cited by 257
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE
(1958) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1958.tb58406.x · Cited by 255
Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease
Lopez, O. L. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.3.310 · Cited by 255
Geldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221
Hutchinson, A. D., & Mathias, J. L. (2007) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.100669 · Cited by 187
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Xu, H., Garcia-Ptacek, S., Jönsson, L., Wimo, A., Nordström, P., & Eriksdotter, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011832 · Cited by 182
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Self-citationHogan, D. B., Bailey, P., Black, S., Carswell, A., Chertkow, H., Clarke, B., Cohen, C., Fisk, J. D., Forbes, D., Man-Son-Hing, M., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.081103 · Cited by 167
An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom
Getsios, D., Blume, S., Ishak, K. J., Maclaine, G., & Hernández, L. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.07.001 · Cited by 144
Donepezil in Vascular Dementia: Combined Analysis of Two Large-Scale Clinical Trials
Román, G. C., Wilkinson, D. G., Doody, R. S., Black, S. E., Salloway, S. P., & Schindler, R. J. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000088494 · Cited by 141
Self-citationDEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE
Cummings, J., & Fox, N. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.12 · Cited by 139
“Symptomatic treatments such as cholinesterase inhibitors have been shown to delay disease progression as measured by cognitive and functional measures[12], and delay of symptoms does not constitute proof of disease-modification.”
BackgroundThe benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer’s disease
Thompson, S., Lanctôt, K. L., & Herrmann, N. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.425 · Cited by 109
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.002 · Cited by 97
“In industry-sponsored RCTs of 6-month [14–19] to 1-year duration [20,21], ChEI monotherapy improved cognition, maintained patient function, and reduced the risk of functional decline compared with placebo in mild-to-moderate AD patients.”
BackgroundSelf-citationSchoenmaker, N., & Van Gool, W. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00884-1 · Cited by 86
Burns, A., Gauthier, S., & Perdomo, C. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1746 · Cited by 71
“…to improve significantly cognition and to stabilise and maintain or produce less than expected decline in global function and activities of daily living in double-blind, placebo-controlled studies of up to one year duration (Rogers et al., 1998a, 1998b; Mohs et al., 2001; Winblad et al., 2001).”
BackgroundSelf-citationSystematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors
Leinonen, A., Koponen, M., & Hartikainen, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124500 · Cited by 64
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Wallin, Å., Minthon, & Wattmo, C. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s24196 · Cited by 50
Bouts, M. J. R. J., Möller, C., Hafkemeijer, A., van Swieten, J. C., Dopper, E., van der Flier, W. M., Vrenken, H., Wink, A. M., Pijnenburg, Y. A. L., Scheltens, P., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170893 · Cited by 47
Wallin, Å. K., Gustafson, L., Sjögren, M., Wattmo, C., & Minthon, L. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079201 · Cited by 45
Metadata
- Authors
- Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group
- Venue
- Neurology
- Published
- 2001-08-14
- Volume
- 57
- Issue
- 3
- Pages
- 481-488
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2047095305
- Cited by
- 503
- References
- 20
- FWCI
- 30.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.